Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Tenax Therapeutics, Inc. (TENX) had Return on Tangible Equity of -54.19% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-52.60M |
|
-- |
|
-- |
|
$56.38M |
|
$-56.38M |
|
$3.79M |
|
$-52.60M |
|
$-52.60M |
|
$-52.60M |
|
$-52.60M |
|
$-52.60M |
|
$-52.60M |
|
$-56.38M |
|
$-56.38M |
|
39.22M |
|
39.22M |
|
$-1.34 |
|
$-1.34 |
|
| Balance Sheet Financials | |
$104.23M |
|
-- |
|
-- |
|
$104.23M |
|
$7.16M |
|
-- |
|
-- |
|
$7.16M |
|
$97.07M |
|
$97.07M |
|
$97.07M |
|
9.31M |
|
| Cash Flow Statement Financials | |
$-35.80M |
|
-- |
|
$38.51M |
|
$94.85M |
|
$97.56M |
|
$2.71M |
|
$19.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.19% |
|
|
Return on Tangible Equity |
-54.19% |
-50.47% |
|
-54.19% |
|
$10.42 |
|
$-0.91 |
|
$-0.91 |
|